Prostate Cancer Clinical Trials in Massachusetts

Showing 261-278 of 278 trials

A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy

NCT00087659

This study is being conducted to compare the effect of an investigational drug versus placebo on bone loss in men with prostate cancer who are receiving Androgen Deprivation Therapy (ADT). The study drug or placebo will be administered every three months of four treatments in one year. In order to participate, male patients 18 years and older must be consecutive veterans from participating Veterans Administration Medical Centers.

Prostate Cancer

Novartis PharmaceuticalsStarted Dec 2003

Tucson, Arizona, United States • Long Beach, California, United States • Washington D.C., District of Columbia, United States +13 more locations

COMPLETEDPhase 326 miles

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

NCT00657904

The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.

Non-metastatic Prostate Cancer

AstraZeneca3,618 participantsStarted Aug 1995

Birmingham, Alabama, United States • Mobile, Alabama, United States • Scottsdale, Arizona, United States +82 more locations

A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

Prostate Cancer Trials in Other Cities

Laparoscopic Vs. Open Prostatectomy Outcomes

Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer

Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone

A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer

Mifepristone (RU-486) in Androgen Independent Prostate Cancer

Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine in Prostate Cancer Patients

The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage

DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer

ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere

Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

Shorter Radiation Schedule for the Treatment of Prostate Cancer

A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer

Other Conditions in Massachusetts